This seminar will explore relevant solutions for accelerating nasal and oral clinical dosage form development.

Hosted by Dr Richard Johnson, Chief Scientific Officer at UK-based CDMO, Upperton Pharma Solutions, this seminar will cover formulation platforms, analytical characterisation techniques, and different particle engineering strategies to enhance drug success rates.

Key learning objectives

• Gain insights on strategies for reducing risks during nasal and oral clinical formulation development.
• Review drug product options for early clinical evaluation.
• Understand the potential advantages of spray drying to address solubility or particle engineering challenges.
• Network with other professionals.
• Speak with our experts during an interactive Q&A session.

Who should attend

• Pharmaceutical researchers and scientists.
• CMC experts on inhalation/nasal and oral drug delivery.
• Nasal and oral product development professionals.

Meet our Experts

Dr. Richard Johnson Founder & Chief Scientific Officer Upperton Pharma Solutions	Dr. Ian Lafferty Chief Technical Officer Upperton Pharma Solutions

Upperton Pharma Solutions is an award-winning UK-based CDMO, specializing in formulation development and clinical trial manufacturing for oral solids, liquids, semi-solids, nasal and inhaled drug products.